# An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

> **NCT06608212** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 150000 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Finerenone (Kerendia, BAY948862)
- **DRUG:** Others except finerenone

## Key facts

- **NCT ID:** NCT06608212
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2025-03-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 150000 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608212, "An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06608212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*